Proteomics

Dataset Information

0

A multiplexed urinary biomarker panel has potential for Alzheimer’s Disease Diagnosis using targeted proteomics and machine learning


ABSTRACT: As disease-modifying therapies are now available for Alzheimer’s disease (AD), accessible, accurate and affordable biomarkers to support diagnosis are urgently needed. We sought to develop a mass spectrometry-based urine test as a high-throughput screening tool for diagnosing AD. We collected urine from a discovery cohort (n=11) of well characterised individuals with AD (n=6) and their asymptomatic, CSF biomarker negative study partners (n=5) and used untargeted proteomics for biomarker discovery. Protein biomarkers identified were taken forward to develop a high-throughput, multiplexed and targeted proteomic assay which was tested on an independent cohort (n=21). The panel of proteins identified are known to be involved in AD pathogenesis. In comparing AD and controls, a panel of proteins including MIEN1, TNFB, VCAM1, REG1B and ABCA7 had a classification accuracy of 86%. These proteins have been previously implicated in AD pathogenesis. This suggests that urine targeted mass spectrometry has potential utility as a diagnostic screening tool in AD.

ORGANISM(S): Homo Sapiens

SUBMITTER: Jenny Hallqvist  

PROVIDER: PXD044751 | panorama | Mon May 04 00:00:00 BST 2026

REPOSITORIES: PanoramaPublic

altmetric image

Publications

A Multiplexed Urinary Biomarker Panel Has Potential for Alzheimer's Disease Diagnosis Using Targeted Proteomics and Machine Learning.

Hällqvist Jenny J   Pinto Rui C RC   Heywood Wendy E WE   Cordey Jonjo J   Foulkes Alexander J M AJM   Slattery Catherine F CF   Leckey Claire A CA   Murphy Eimear C EC   Zetterberg Henrik H   Schott Jonathan M JM   Mills Kevin K   Paterson Ross W RW  

International journal of molecular sciences 20230906 18


As disease-modifying therapies are now available for Alzheimer's disease (AD), accessible, accurate and affordable biomarkers to support diagnosis are urgently needed. We sought to develop a mass spectrometry-based urine test as a high-throughput screening tool for diagnosing AD. We collected urine from a discovery cohort (n = 11) of well-characterised individuals with AD (n = 6) and their asymptomatic, CSF biomarker-negative study partners (n = 5) and used untargeted proteomics for biomarker di  ...[more]

Similar Datasets

2019-12-22 | GSE128720 | GEO
2012-04-30 | E-GEOD-33839 | biostudies-arrayexpress
2012-05-01 | GSE33839 | GEO
2023-02-16 | PXD022649 | Pride
2013-12-31 | E-GEOD-35222 | biostudies-arrayexpress
2013-12-31 | GSE35222 | GEO
2024-05-17 | GSE240729 | GEO
2015-08-05 | GSE63060 | GEO
2020-11-18 | GSE144858 | GEO
2015-08-05 | GSE63061 | GEO